Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сиэтл Дженетикс, Инк.filedCriticalСиэтл Дженетикс, Инк.
Priority claimed from PCT/US2018/058613external-prioritypatent/WO2019089870A1/en
Publication of EA202091087A1publicationCriticalpatent/EA202091087A1/en
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents
(AREA)
Abstract
Настоящее изобретение в целом относится к способам улучшения нежелательных явлений у субъектов с лимфомой из зрелых Т-клеток, получающих лечение конъюгатом "антитело против CD30-лекарственное средство" в комбинации с сопутствующей химиотерапией. Нежелательные явления включают периферическую невропатию и нейтропению.The present invention generally relates to methods for ameliorating adverse events in subjects with mature T cell lymphoma receiving anti-CD30 antibody drug conjugate treatment in combination with concomitant chemotherapy. Adverse events include peripheral neuropathy and neutropenia.
EA202091087A2018-10-012018-11-01
METHODS FOR REDUCING THE SIDE EFFECTS OF THERAPY WITH ANTIBODY AGAINST CD30-DRUG CONJUGATE
EA202091087A1
(en)